bempedoic acid vs ezetimibe
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of bempedoic acid and ezetimibe. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine concentrations. The degree of increase in ezetimibe exposure may be greater in patients with severe renal insufficiency [see Clinical Pharmacology (12.3) ] .
Nexletol
Zetia
No summary available.
No summary available.
Information not available.
Information not available.
Information not available.
Information not available.
- • Upper respiratory tract infection
- • Muscle spasms
- • High uric acid levels in the blood
- • Back pain
- • Stomach pain or discomfort
- • Headache
- • Upper respiratory tract infection
- • Muscle pain
- • Diarrhea
- Myalgia 335
- Arthralgia 214
- Muscle Spasms 153
- Pain In Extremity 135
- Nausea 130
- Fatigue 4,663
- Nausea 4,195
- Myalgia 4,191
- Diarrhoea 3,662
- Dizziness 3,338
No specific warnings noted.
No specific warnings noted.
No pregnancy information available.
No pregnancy information available.
How to Read This bempedoic acid vs ezetimibe Comparison
bempedoic acid is classified in the ACL Inhibitor drug class, while ezetimibe sits within the Cholesterol Absorption Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, bempedoic acid has 967 submissions while ezetimibe has 20,049. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to taking these medications together can cause the levels of both drugs to increase in your bloodstream.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for bempedoic acid or ezetimibe.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.